Benitec Biopharma Net Worth
Benitec Biopharma Net Worth Breakdown | BNTC |
Benitec Biopharma Net Worth Analysis
Benitec Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Benitec Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Benitec Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Benitec Biopharma's net worth analysis. One common approach is to calculate Benitec Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Benitec Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Benitec Biopharma's net worth. This approach calculates the present value of Benitec Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Benitec Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Benitec Biopharma's net worth. This involves comparing Benitec Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Benitec Biopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Benitec Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Benitec Biopharma's net worth research are outlined below:
| Benitec Biopharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 216 K. Net Loss for the year was (21.75 M) with profit before overhead, payroll, taxes, and interest of 75 K. | |
| Benitec Biopharma Ltd currently holds about 4.06 M in cash with (19.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Benitec Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Benitec Biopharma to Participate in Upcoming Investor Conferences in December |
Benitec Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Benitec Biopharma Ltd. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Benitec Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Benitec Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Benitec Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Benitec Biopharma Ltd backward and forwards among themselves. Benitec Biopharma's institutional investor refers to the entity that pools money to purchase Benitec Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lion Point Capital, Lp | 2024-09-30 | 39 K | Longwood Capital Partners Llc | 2024-09-30 | 29.8 K | Blackrock Inc | 2024-06-30 | 28 K | Northern Trust Corp | 2024-09-30 | 24.8 K | Citadel Advisors Llc | 2024-09-30 | 14.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 11.2 K | Gamma Investing Llc | 2024-09-30 | 6.5 K | Ubs Group Ag | 2024-06-30 | 2 K | Tower Research Capital Llc | 2024-06-30 | 891 | Suvretta Capital Management, Llc | 2024-06-30 | 1.7 M | Hhg Plc | 2024-06-30 | 900.8 K |
Follow Benitec Biopharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 215.39 M.Market Cap |
|
Project Benitec Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (0.46) | (0.48) |
When accessing Benitec Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Benitec Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Benitec Biopharma's profitability and make more informed investment decisions.
Please note, the presentation of Benitec Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Benitec Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Benitec Biopharma's management manipulating its earnings.
Evaluate Benitec Biopharma's management efficiency
Benitec Biopharma has return on total asset (ROA) of (0.496) % which means that it has lost $0.496 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9168) %, meaning that it created substantial loss on money invested by shareholders. Benitec Biopharma's management efficiency ratios could be used to measure how well Benitec Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.44. In addition to that, Return On Capital Employed is expected to decline to -0.5. At present, Benitec Biopharma's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 54.3 M, whereas Other Current Assets are forecasted to decline to about 480.1 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 11.64 | 11.06 | |
| Tangible Book Value Per Share | 11.64 | 11.06 | |
| Enterprise Value Over EBITDA | 0.94 | 0.99 | |
| Price Book Value Ratio | 0.62 | 0.59 | |
| Enterprise Value Multiple | 0.94 | 0.99 | |
| Price Fair Value | 0.62 | 0.59 | |
| Enterprise Value | -21.1 M | -20 M |
Understanding the operational decisions made by Benitec Biopharma management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 10.5 K | Revenue 7 K | Quarterly Revenue Growth 0.125 | Revenue Per Share 0.003 | Return On Equity (0.92) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Benitec Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Benitec Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Benitec Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Suvretta Capital Management, Llc over a week ago Acquisition by Suvretta Capital Management, Llc of 3076 shares of Benitec Biopharma at 10.22 subject to Rule 16b-3 | ||
Suvretta Capital Management, Llc over a week ago Acquisition by Suvretta Capital Management, Llc of 1570 shares of Benitec Biopharma at 9.73 subject to Rule 16b-3 | ||
Mehta Kishan over three months ago Insider Trading | ||
Smith Edward F over six months ago Acquisition by Smith Edward F of 12000 shares of Benitec Biopharma subject to Rule 16b-3 | ||
Megan Boston over six months ago Acquisition by Megan Boston of 200004 shares of Benitec Biopharma at 5.21 subject to Rule 16b-3 | ||
Buchi J Kevin over six months ago Acquisition by Buchi J Kevin of 35000 shares of Benitec Biopharma subject to Rule 16b-3 | ||
Megan Boston over a year ago Purchase by Megan Boston of 25907 shares of Benitec Biopharma | ||
Jerel Banks over a year ago Acquisition by Jerel Banks of 356900 shares of Benitec Biopharma subject to Rule 16b-3 |
Benitec Biopharma Corporate Filings
F4 | 21st of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 18th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 7th of November 2024 Other Reports | ViewVerify |
Benitec Biopharma Earnings per Share Projection vs Actual
Benitec Biopharma Corporate Management
| Michael Graham | Founding Scientist and Head of Discovery | Profile | |
| Bryan Dulhunty | Chief Officer | Profile | |
| Claudia Kloth | Senior Manufacturing | Profile | |
| Craig Lewis | Chief Adviser | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.51) | Revenue Per Share 0.003 | Quarterly Revenue Growth 0.125 | Return On Assets (0.50) | Return On Equity (0.92) |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.